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Infections with human parechoviruses (HPeVs) are prevalent in young children and have been associated
with mild gastroenteritis and, less frequently, with meningitis and neonatal sepsis. To investigate the involve-
ment of these viruses in respiratory disease, a highly sensitive nested PCR was used to screen a large archive
of respiratory specimens, collected between January and December 2007. Respiratory samples had previously
been tested for eight respiratory viruses, including respiratory syncytial virus and adenovirus, by PCR. HPeV
was detected in 34 of 3,844 specimens, representing 27 of 2,220 study subjects (1.2%). HPeV types were
identified by sequencing the VP3/VP1 junction amplified by PCR directly from clinical specimens. The assay
could amplify all HPeV types examined with high sensitivity (types 1 and 3 to 6) and also identified HPeV types
in all but one of the screen-positive study specimens (25 HPeV1 and eight HPeV6 specimens). Infections with
both HPeV1 and HPeV6 were seasonal, with highest frequencies in July and August, and restricted to children
aged between 6 months and 5 years. Other respiratory viruses were frequently codetected in HPeV-positive
specimens, with significant overrepresentation of adenovirus coinfections (37%). Most HPeV-positive speci-
mens were referred from emergency departments, although no association with specific respiratory symptoms
or disease was found. In summary, the low frequency of detection and lack of clear disease associations indicate
that HPeV1 and -6 are not major pathogens in individuals presenting with respiratory disease. However, the
screening and typing methods developed will be of value in further HPeV testing, including testing for
meningitis cases and other suspected HPeV-associated disease presentations.
Human parechoviruses (HPeVs) are single-stranded, posi-
tive-sense RNA viruses in the Parechovirus genus within the
large family of Picornaviridae. The prototype strains, HPeV1
and -2, were previously designated echovirus 22 and 23 in the
Enterovirus genus but were renamed and reclassified into their
own genus in 1999 based on evident differences in genome
organization and structure, as well as divergence of encoded
proteins and biological properties (17, 27). Although these first
HPeV types were discovered during a summer diarrhea out-
break in children over 50 years ago (31), it was only recently
that four additional HPeV types were discovered. To date,
HPeV3, -4, -5, and -6 have been identified in Japan, The
Netherlands, the United States, Canada, and Germany (3, 4, 6,
18). HPeV infections are commonly observed to occur in the
general population; at least 95% of the adult population are
seropositive for HPeV1-specific antibodies (20, 28). In addi-
tion, it has been shown that HPeV infections are often ac-
quired in early childhood, with the median age of acquiring
HPeV1 infection being 18 months and with 20% of children
being infected after the first year of life (28).
HPeV1 infections have generally been associated with mild
gastrointestinal and respiratory infections (13, 15, 31), as well
as with occasional cases of necrotizing enterocolitis (10), en-
cephalitis (21), and Reye’s syndrome (30). Although HPeV2
has been associated mostly with gastroenteritis, these infec-
tions seem to be very rare. In addition to HPeV2, HPeV6 has
been suggested as another causative agent of children’s diar-
rhea (4). An association between HPeV3 infection and sepsis-
like illness, including central nervous system involvement in
neonates, has recently been established (1, 7, 11), whereas the
role of HPeV4 and -5 as human pathogens is still poorly un-
derstood (6, 12).
Although HPeVs are frequently isolated from patients with
respiratory infection and are thought to be associated with
disease (13, 15), HPeVs are not yet commonly included in
respiratory screening. Currently, PCR-based screening for
well-established pathogenic viruses, including respiratory syn-
cytial virus (RSV), parainfluenza viruses 1 to 3 (PIV1 to PIV3),
influenza A and B viruses (FLUA and FLUB, respectively),
adenovirus (AdV), and, more recently, human metapneumo-
virus (HMPV) and human bocavirus (HBoV) (a new parvovi-
rus), detects virus infection in a majority of often-severe respi-
ratory infections (19). However, a substantial proportion of
viral respiratory infections are thought to remain undiagnosed,
not least because several other viruses associated with upper
and lower respiratory tract (URT and LRT, respectively) in-
fections, including coronaviruses, enteroviruses, and rhinovi-
ruses, are frequently unscreened.
To investigate the involvement of HPeV in respiratory dis-
ease, referred diagnostic respiratory samples from 2007 in
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Scotland were screened for HPeV by nested reverse transcrip-
tion-PCR (RT-PCR). The results of diagnostic testing for
other viruses and referral and epidemiological information
recorded for the samples were combined to enable a compar-
ison of the epidemiologies and clinical associations. As a part
of this study, a highly sensitive HPeV typing method, which can
be applied directly to clinical specimens rather than to cultured
virus, was developed. This assay provides the starting point for
future investigations of potential epidemiological and clinical
differences between HPeV types.
MATERIALS AND METHODS
Test specimens. The study was based on a total of 4,173 respiratory samples
referred to the Specialist Virology Centre (SVC), Royal Infirmary of Edinburgh,
for respiratory virus testing from 1 January to 31 December 2007. The specimens
comprised the following: 2,259 nasopharyngeal swabs or aspirates, 1,317 nose
and/or throat swabs, 201 tracheal swabs or aspirates, 153 sputum samples, 152
bronchoalveolar lavage specimens, 41 bronchial washings, and 50 “other” types
recorded. Routine respiratory virus detection was composed of nested PCR for
RSV, FLUA, FLUB, PIV1 to PIV3, and AdV based on previously described
assays (16, 29). HPeV-positive samples were additionally screened for HBoV as
previously described (22) but using a “detuned” single-round PCR protocol
capable of detecting only high-viral-load samples, as recently advocated (2), and
for HMPV by nested PCR using primers for the F gene (E. Gaunt, K. Temple-
ton, and P. Simmonds, unpublished data).
All samples were anonymized and deposited in the SVC respiratory sample
archive prior to testing. Approval was obtained from the Lothian Regional Ethics
Committee (08/S11/02/2) to retain information during the anonymization process
for epidemiological purposes while strictly protecting patient confidentiality. The
stored data included age band, partial postcode, any recorded symptoms or
clinical information, referral source, month of sample collection, and results of
other virological testing of the sample.
HPeV1 and -3 isolates cultured on Vero cells were used as assay controls. A
proficiency panel was obtained from Quality Control on Molecular Diagnostics
(QCMD, Glasgow, United Kingdom). In addition, 21 previously typed clinical
isolates (13 HPeV1, four HPeV3, two HPeV4, one HPeV5, and one HPeV6
isolate) were investigated using a modification of a previously described VP1-
based PCR method (8), along with 26 nontypeable samples positive by 5 un-
translated region (5 UTR) screening but negative by VP1 PCR.
HPeV detection. RNA was extracted from 100 l of clinical specimens by using
a MinElute virus spin kit according to the manufacturer’s instructions (Qiagen,
Hemel Hempstead, United Kingdom). Extracted RNA was stored at 70°C. A
nested RT-PCR method was used for HPeV screening, initially carried out in
pools of 10, with positive pools split into individual components and retested to
identify positive samples.
RNA from pools or individual samples was reverse transcribed into cDNA by
use of a reverse transcription system (Promega, United Kingdom). The RT step
was performed in a reaction volume of 20 l per the manufacturers’ instructions
but using 5 l of the extracted RNA. The reaction mixtures were incubated at
room temperature for 10 min and at 42°C for 60 min and then heated to 95°C for
5 min and placed on ice for 5 min. cDNA was either used directly for PCR or
stored frozen at 20°C.
The primers which target the highly conserved 5UTR are as follows (with the
positions of the HPeV1 prototype strain [L02971] in parentheses): outer sense
and antisense primers 5GGGTGGCAGATGGCGTGCCATAA (253) and 5C
CTRCGGGTACCTTCTGGGCATCC (583) and inner sense and antisense
primers 5YCACACAGCCATCCTCTAGTAAG (313) and 5GTGGGCCTTA
CAACTAGTGTTTG (556). Amplification was performed using 0.4 U of GoTaq
Taq polymerase (Promega, United Kingdom) and the manufacturers’ amplifica-
tion buffer containing a final concentration of 1.5 mM MgCl2, 0.5 M primers,
and 30 M deoxynucleoside triphosphates in a 20-l reaction volume for both
rounds of PCR. In the first-round PCR, 2 l of cDNA was amplified using the
following parameters: 30 cycles of 18 s at 94°C, 21 s at 50°C, and 90 s at 72°C,
combined with a final extension of 5 min. One microliter from the first-round
PCR was used as the template in a second round of PCR and amplified using the
same cycling parameters, except that the annealing step was performed at 55°C.
PCR products were run on 2% agarose gels prestained with ethidium bromide to
identify positive samples with a predicted size of 243 bp. Positive pools were split
and the above-described nested RT-PCR was repeated to identify individual
positive samples. To evaluate assay sensitivity, HPeV samples on enterovirus
proficiency panel 2008 from QCMD were tested.
Parechovirus typing. For parechovirus typing, samples positive by the 5 UTR
PCR were amplified using primers from the VP3/VP1 junction region and a
SuperScript III one-step RT-PCR kit (Invitrogen, United Kingdom) according to
the manufacturer’s instructions. Primers, with the positions in relation to L02971
shown in parentheses, were outer sense and antisense primers 5GAYAATGC
YATMTAYACWATYTGTGA (2090) and 5ACWGTRAARATRTCHACAT
TSATDG (2523) and inner sense and antisense primers 5TTYTCMACHTGG
ATGMGGAARAC (2159) and 5DGGYCCATCATCYTGWGCTGA (2458).
Each combined RT-PCR was carried out in a 20-l reaction volume of the
manufacturers’ supplied buffer (containing 0.4 mM deoxynucleoside triphos-
phates and 2.4 mM MgSO4), 6 l of extracted RNA, 0.8 l of Superscript III
RT/Platinum Taq polymerase, and 0.5 M of outer VP3/VP1 primers. The RT
and PCR cycling conditions for the first round were, sequentially, 43°C for 1 h
and 20 cycles of 53°C (1 min) and 55°C (1 min), followed by 70°C for 15 min and
94°C for 2 min. PCR comprised 40 cycles of 94°C (30 s), 50°C (30 s), and 68°C
(105 s) and a final extension at 68°C for 5 min. One microliter of the product was
transferred for a second PCR, which was performed as described for the 5 UTR
PCR but with the VP3/VP1 inner primers. The final product of 304 bp was
visualized by agarose gel electrophoresis as described above.
Amplified DNA was directly sequenced using a BigDye Terminator kit (Ap-
plied Biosystems, Warrington, United Kingdom) in both directions, from which
a complete sequence between positions 2182 and 2437 was assembled. Type
identification was achieved by phylogenetic analysis of nucleotide and inferred
amino acid sequences using a data set containing sequences from published
HPeV variants of previously assigned HPeV types.
Nucleotide sequence accession numbers. Nucleotide sequences from the VP3/
VP1 region have been assigned the GenBank accession numbers FJ009260 to
FJ009290.
RESULTS
Study group. A total of 3,844 respiratory samples (83%
nasopharyngeal swabs or aspirates) from 2,200 different indi-
viduals (1,211 male, 989 female) were available from the ar-
chive for HPeV screening. These represent 92% of all samples
referred to the SVC for respiratory virus screening between
January 2007 and December 2007. These samples were re-
ferred equally from all age groups, with good representation of
samples from very young children (9.5% under 3 months) and
older patients (13.3% over 65 years). Over 95% of study sub-
jects were treated in accident and emergency (A&E) depart-
ments or inpatient wards in referral hospitals in Edinburgh and
surrounding areas.
All samples were screened for a range of respiratory viruses
by multiplexed nested PCR for RSV, FLUA and FLUB, PIV1
to PIV3, and AdV. The following viruses were detected in the
study samples: RSV in 584 samples, FLUA in 127 samples,
FLUB in 0 samples, PIV1 in 44 samples, PIV2 in 27 samples,
PIV3 in 109 samples, and AdV in 329 samples. The total
number of samples in which respiratory viruses were detected
was 1,220 (32%, from 930 patients), of which 101 were coin-
fections of two viruses. Most often, coinfections consisted of
RSV and AdV (n  54), but other viruses were also found in
coinfected individuals, including PIV3/AdV (25 samples),
PIV1/AdV (three samples), PIV2/AdV (two samples), FLUA/
AdV (one sample), PIV3/RSV (five samples), FLUA/RSV
(five samples), PIV2/RSV (four samples), and PIV1/RSV (two
samples). In addition, two triple infections were recorded
(RSV/AdV/PIV2 and RSV/AdV/PIV3; one each). None of the
multiple infections were detected in consecutive samples from
the same individual.
Frequency of HPeV infections. The sensitivity of the screen-
ing PCR (using 5 UTR primers) for HPeV RNA was assessed
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by using the QCMD 2008 panel for detection of enteroviruses,
which contained two HPeV3 specimens (EV08-03 and EV08-
08). Both samples were detected by our new HPeV PCR assay.
Sample EV08-03 contained a low level of HPeV RNA (stock
dilution of 1.0  107), and HPeV was detected in samples
from less than one-third of the participants (30.7%).
The 3,844 study samples were screened for HPeV RNA
sequences by nested RT-PCR, initially in pools of 10; positive
pools were split to identify individual positive samples. For
HPeV, a total of 34 individual positive samples were identified
with the screening primers from the 5 UTR; all except one
were also positive by RT-PCR using primers from the VP3/
VP1 gene region (0.8% sample prevalence). These 33 con-
firmed samples were taken from a total of 27 different individ-
uals, yielding an overall study subject prevalence of infection of
1.2% in the study group. Interestingly, HPeV was detected
more often in males than females (male-to-female ratio of
2.4:1), demonstrating a higher prevalence among males (1.5%,
compared to 0.8% in females). Other respiratory viruses were
frequently codetected in the HPeV-positive samples (25 of 33),
of which 22 were coinfections of two viruses (with AdV [n 
10], RSV [n  9], PIV3 [n  2], or PIV1 [n  1]) and three
were triple infections (HPeV/AdV/RSV [n  2] and HPeV/
AdV/PIV3 [n  1]).
RSV was the most frequently detected virus, amplified from
584 samples from 481 different individuals, followed by AdV
(329 samples from 240 individuals). FLUA was detected in 127
samples from 94 individuals, whereas no FLUB was found in
the study year 2007. PIV3 was the most often diagnosed para-
influenza virus, with 109 positive samples collected from 90
individuals (PIV1 was found in 44 samples from 32 individuals
and PIV2 in 27 samples from 23 individuals).
HPeV typing assay. The region amplified by the VP3/VP1
primers was highly variable and allowed previously assigned
HPeV types to be reliably differentiated. Pairwise distances
between and within types of both nucleotide and translated
amino acid sequences formed nonoverlapping distributions
(Fig. 1A), with thresholds of 18% divergence for nucleotide
and 8% divergence for amino acid dividing the intra- and
intertype categories. This division is reflected in separate phy-
logenetic groupings of previously published and typed se-
quences (Fig. 1B). The only exception was the highly divergent
Harris HPeV1 isolate, designated the type member of the
parechoviruses but substantially divergent from other pub-
lished HPeV1 sequences in the amplified region.
To investigate the sensitivity of the typing assay, we reas-
sayed a series of 47 clinical specimens identified as positive by
5 UTR screening, 21 of which had been typed by VP1 se-
quencing (8) and 26 of which were nontypeable by this method
(Table 1). The VP3/VP1 PCR was followed by sequencing, and
a much higher frequency of samples overall (including 21 of
the 26 previously nontypeable samples) was successfully am-
plified and sequenced, including 15 type 1, three type 3, one
type 4, and two type 5 HPeV variants. The method was applied
to identify the HPeV types in the samples found to be positive
by the respiratory screen (Fig. 1C). All but 1 of the 34 HPeV-
positive samples could be amplified using the VP3/VP1 prim-
ers, and sequences from the amplicons grouped closely with
either HPeV type 1 (EF051629; 25 specimens from 22 study
subjects) or type 6 (AB252582; eight specimens from five in-
dividuals) sequences, providing unequivocal HPeV type assign-
ments. Identical or closely similar sequences were obtained
from the three study subjects providing multiple positive sam-
ples.
Epidemiological and clinical associations of HPeV infec-
tions. Sample and study subject information was recorded for
each sample tested and was available in anonymized form for
analysis of virus epidemiology and clinical associations. The
analysis of seasonal variation was based on sample totals,
whereas the age profiles were based on study subject totals to
prevent overrepresentation of individuals from whom multiple
samples were referred.
HPeV infections were restricted entirely to children aged
between 6 months and 5 years (Fig. 2A). The five study sub-
jects with HPeV6 infections were distributed throughout the
age range (two were 7 to 12 months old, one was 1 to 2 years
old, and two were 3 to 5 years old). Although RSV tended to
infect neonates more frequently than HPeV, RSV infections
showed a similar age profile, with infections confined almost
completely to young children. Similarly, AdV showed the high-
est frequencies in the age group from 6 months to 5 years but
lower frequencies in very young children. Greater numbers are
FIG. 1. Identification of HPeV types by sequence comparisons of the VP3/VP1 regions. (A) Frequency histogram of pairwise distances between
(gray bars) and within (black bars) HPeV types, determined using published assignments. Nucleotide p (uncorrected) distances and inferred
translated amino acid sequence p distances are shown. (B) Phylogenetic analysis of the same data set, carried out using neighbor-joining trees
based on maximum composite likelihood (nucleotide) distances and amino acid p distances. Bootstrap resampling was used to demonstrate the
robustness of groupings; values of 70% are shown (percentages are shown at left). For clarity, symbols depicting sequences of HPeV2 are black,
those depicting sequences of HPeV1 and HPeV4 to -6 are different shades of gray, and those depicting sequences of HPeV3 are white. GenBank
accession numbers are indicated. (C) Phylogenetic analysis of sequences from clinical specimens (HPeV1, white circles; HPeV6, gray circles),
determined by the same method using the single reference sequence of each HPeV type (black circles).
TABLE 1. Sensitivity and specificity comparison of HPeV VP3/VP1
typing of previously typed specimens
VP3/VP1
sequencing
type
No. of specimens of preassigned
typea:
No. of
specimens
not typeda
Total
1 2 3 4 5 6
1 12 15 27
2 0
3 4 3 7
4 2 1 3
5 1 2 3
6 1 1
Negative 1 5 6
Total 13 0 4 2 1 1 26 47
a By VP1 sequencing (see reference 8).
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needed to determine whether the incidences of HPeV1 and -6
(and of other types) show different age distributions.
The frequencies of HPeV infection varied substantially
over the study period (Fig. 2B), with a high rate of HPeV
detection in late summer (July and August) and early winter
(November and December). Incidences of RSV and FLUA
infections also showed seasonal variation, with peaks during
the midwinter from November to February, while AdV
showed a relatively constant frequency of infection through-
out the year. Infections with HPeV1 and -6 were found
throughout the sampling period, with no evidence of differ-
ences in seasonal prevalence (from low numbers tested)
(data not shown).
HPeV was detected more frequently in samples with other
respiratory viruses present, with over two-thirds of HPeV-pos-
itive samples containing another virus (Table 2). These fre-
quencies were substantially higher than those observed for
other respiratory viruses, AdV being the highest, with code-
tected viruses in 86 of 201 study subjects under the age of 5
years (43%). For the HPeV-positive subjects, AdV and RSV
were the most frequently codetected viruses (Table 3), al-
though in the latter case this frequency (9 of 27; 33%) was
similar to that observed for HPeV-negative individuals (415 of
1,243; 33%) (P  1.00). It was only with AdV that a signifi-
FIG. 2. Epidemiology of HPeV and other respiratory viruses. Comparison of (A) age distributions and (B) referral months of HPeV infections
with those of other frequently detected viruses (RSV, FLUA, PIV3, and AdV). Numbers above bars show numbers of samples (A) or study subjects
(B) positive for HPeV. m, months; y, years.
TABLE 2. Frequencies of virus codetection in study subjects
(5 years) infected with HPeV and other viruses
Virus No. of coinfected subjects/total no. of subjects (%)
HPeV............................................................................... 19/27 (70)
Other viruses
RSV............................................................................. 70/424 (17)
FLUA.......................................................................... 4/51 (8)
PIV1 ............................................................................ 5/24 (21)
PIV2 ............................................................................ 7/13 (54)
PIV3 ............................................................................ 30/70 (43)
AdV............................................................................. 86/201 (43)
Total for other virusesa.............................................100/783 (13)
a Excluding HPeV.
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cantly higher frequency of codetection with HPeV was identi-
fied (37%, compared with 15% [P  0.006]).
Finally, referral information, including the source of samples
and reported symptoms of HPeV-positive samples, was com-
pared with those of other commonly detected respiratory vi-
ruses (Fig. 3). Over half of the HPeV-positive samples origi-
nated from A&E departments, a proportion similar to that of
RSV but higher than those of AdV and FLUA. The distribu-
tion was distinct from that of samples in which no viruses were
detected, in which cases inpatient and critical care unit referral
predominated. Although the referral source data suggest that
HPeV may present with acute respiratory disease (as typically
occurs for RSV), an analysis of clinical data indicated a much
higher frequency of samples originating from subjects without
respiratory symptoms (approximately 40% of cases, similar to
that for samples in which no virus was isolated). In contrast,
over 80% of RSV-positive samples originated from individuals
with respiratory, particularly LRT, symptoms.
DISCUSSION
This is the first systematic study of the incidence, epidemi-
ology, and clinical associations of HPeV infections detected in
respiratory samples. The study used a newly developed sensi-
tive and specific nested RT-PCR amplification method with
highly conserved primers from the 5 UTR capable of detect-
ing all HPeV types; the sense primers hybridized to conserved
regions between positions 235 and 335 distinct from primer
targets used in other published 5UTR-based assays for HPeV
(5, 24, 26), while the antisense primers (positions 534 to 583)
overlapped probe or primer sites used in these other assays. Its
very high sensitivity (as demonstrated using the QCMD panel)
also indicated its potential suitability for screening cerebrospi-
nal fluid from meningitis cases, where viral loads are likely to
be low.
The direct typing of HPeV by VP3/VP1 PCR and sequenc-
ing proved similarly highly sensitive, enabling its use directly on
clinical specimens and providing an epidemiological tool much
more useful than previously used methods based on serotyping
or sequencing HPeV isolates (12, 30); parechoviruses often
grow poorly in culture, and antibodies used for typing are not
widely available for more recently discovered HPeV types. By
use of the panel of previously typed and nontypeable clinical
specimens, our new typing method identified HPeV in all but
one of the typed samples (20/21) and most of the samples
previously refractory to amplification with VP1 primers (8).
The high sensitivity of this method demonstrates its potential
value in future investigations of the molecular epidemiology of
different HPeV types and possible differences in disease asso-
ciations and tropism for the central nervous system.
HPeV incidence and epidemiology. Despite the sensitivity of
the screening method used in the current study, we found a
relatively low frequency of HPeV infections in the study pop-
ulation (27 of 2,200 different study subjects investigated). Sev-
eral features of seasonal and age distribution are, however,
concordant with previous investigations of HPeV epidemiol-
ogy, including the observed greater frequencies of infections in
late summer and early winter months (13) and an age range of
infection restricted to individuals under 5 years old (7, 13). The
absence of any detectable HPeV infections in older children
and adults (despite representing 37% of the total 3,844 sam-
ples in the archive) is consistent with previous seroepidemio-
logical studies documenting 72% seroprevalence of antibodies
to HPeV1 by the age of 2, reaching 99% in adulthood (28).
Although HPeV1 was the most common type detected in the
study population in Scotland, the relatively frequent detection
of type 6 represents the first report of this type from the United
Kingdom and confirms previous data indicating its wide geo-
graphical distribution (4, 7, 24, 30). Recent studies have pro-
FIG. 3. Referral sources and presenting symptoms of study subjects
infected with HPeV and other respiratory viruses. Relative proportions of
total study group infected with each virus originating from A&E depart-
ments, general hospital wards, and critical care wards (high-dependency
unit [HDU]/intensive care unit [ICU]) (other sources [e.g., general prac-
titioners] have been excluded because of low numbers) (top) and present-
ing symptoms broadly categorized into LRT, URT, and those unrelated to
respiratory infections (Non-resp) (bottom).
TABLE 3. Frequencies of detection of other viruses in HPeV-infected
and uninfected subjects (5 years)
Virus
No. of HPeV-coinfected
subjects/total no. of
subjects (%)
No. of HPeV-negative
subjects/total no. of
subjects (%)
P valuea
Any virus 19/27 (70) 656/1,243 (53) 0.08
RSV 9/27 (33) 415/1,243 (33) 1.00
AdV 10/27 (37) 191/1,243 (15) 0.006
PIV3 2/27 (7) 68/1,243 (5) 0.66
a Calculated by Fisher’s exact test. The value below 0.05 appears in bold.
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vided evidence for a biannual cycle of HPeV infections, par-
ticularly evident with HPeV3 infections, which occur most
frequently in even-numbered years in The Netherlands (32; K.
Benschop, X. Thomas, C. Serpenti, R. Molencamp, and K.
Wolthers, unpublished data). If this pattern is shared through-
out Europe, it might explain the absence of HPeV3 infections
in the current study.
Clinical significance of HPeV infections. It has been claimed
that HPeV1 is a common cause of respiratory disease, includ-
ing URT and LRT illnesses (13, 15). In addition, HPeV1 has
been identified as a cause of nosocomial respiratory infections
involving neonates and small children (9, 14). A retrospective
investigation of 109 individuals with HPeV1 infection demon-
strated respiratory symptoms in 13% of study subjects (13),
similar to the 26% frequency in a larger series of 581 cases of
HPeV1 and HPeV2 infections (15). Among a group of prema-
ture infants in a neonatal ward with respiratory disease,
HPeV1 was isolated from 18/64 individuals, of which 11 had
URT symptoms and seven had pneumonia, although a range of
other respiratory viruses was detected in the study group (9).
Recently, a few isolated cases of HPeV infections have been
associated with respiratory tract infections (7, 18, 30), although
as with the studies described above (13, 15), other potential
viral or bacterial causes for the observed respiratory disease
were not always excluded.
In contrast to these previously claimed disease associations,
our study does not necessarily provide evidence confirming the
proposed etiological role of HPeV in childhood respiratory
disease. The observed incidence of HPeV infections in respi-
ratory samples (27 of 1,299 study subjects less than 5 years of
age; 2.1%) is arguably not different from the expected fre-
quency of HPeV infections occurring in the general popula-
tion. There are little data on the duration of HPeV shedding
from the respiratory tract during primary infections of immu-
nocompetent individuals. However, a ballpark estimate of 1 to
3 weeks of virus shedding detectable by a highly sensitive PCR
such as that used in the current study, based on durations of
detection of other respiratory viruses and combined with the
documented 70% seroprevalence for HPeV1 antibodies by the
age of 2 years, would predict HPeV detection frequencies of
0.7% to 2.1% (assuming they occur at constant frequency be-
tween the ages of 6 and 24 months). The observed frequency of
1.9% HPeV-positive study subjects from children aged less
than 2 years old thus lies within the range of the expected
detection frequency in the nonhospitalized population. HPeV-
infected individuals are not overrepresented among individuals
presenting predominantly with respiratory symptoms or diag-
nosed respiratory disease, and thus it might be reasoned that
the detection of HPeV is incidental to the respiratory disease
and/or other clinical presentation that led to hospital admis-
sion and sampling.
Some (but not all) aspects of the data collected in the cur-
rent study were consistent with this interpretation. First, over
two-thirds of children in whom HPeV was detected were coin-
fected with another respiratory virus that might account for the
observed respiratory disease (Table 3; Fig. 3B). An alternative
interpretation of the observed high rate of coinfection might be
that HPeV plays an exacerbating role in other respiratory virus
infections, as has been suggested for HBoV (23). Second, al-
though a direct etiological role in respiratory disease might be
considered in the remaining third of cases where HPeV was
the only virus detected, this frequency was actually lower than
that of samples in the archive negative for all routinely
screened respiratory viruses (70%), indicating that a substan-
tial proportion of viruses or bacteria causing respiratory dis-
ease are undetected by current diagnostic screening. However,
it was interesting that AdV infections were specifically associ-
ated with HPeV; 10 of 27 HPeV cases were coinfections with
AdV, significantly greater than codetection frequencies for
HPeV-negative samples (15%) (Table 3) and comparable to
those with other respiratory viruses (43%) (Table 2). One
possibility here is that primary HPeV infections may reactivate
AdV, leading to respiratory disease.
In the current anonymized study design, the only clinical
information available for the study subjects was that recorded
on the specimen referral forms. Nevertheless, the available
data did show the expected association of LRT symptoms with
RSV infections and of URT symptoms with PIVs and AdV and
a higher frequency of absent or nonrespiratory symptoms from
study subjects whose samples were virus negative on screening
(Fig. 3). The data collection procedure and study design used
in the Edinburgh respiratory sample archive was previously
able to demonstrate the association of HBoV infections with
LRT disease at frequencies approaching that of RSV (22) and
a lack of respiratory disease associations with WU and KI
polyomaviruses (25). Based on the available data, HPeV-pos-
itive samples showed a clinical profile with approximately
equal frequencies of LRT, URT, and nonrespiratory symptoms
that most closely matched that of screen-negative samples. It
was distinct from those of RSV and other routinely screened
respiratory viruses and is therefore consistent with a poten-
tially incidental role of HPeV in respiratory disease in the
study subjects.
In the future, the screening and typing methods developed in
the current study will clearly be of value in more-focused test-
ing of individuals with specific illnesses of possible viral etiol-
ogy, such as neonatal sepsis and meningitis. With evidence for
the involvement of HPeV in viral meningitis and possible type-
associated differences in viral tropism and disease (7), the
ability to detect and type HPeV directly from cerebrospinal
fluid would greatly enhance diagnostic testing for these dis-
eases.
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